CRSP analyst estimates
CRISPR Therapeutics (CRSP) analyst ratings, the average price target and its range, and every firm's latest call.
CRSP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 15, 2026 | UBS | Crispr Therapeutics initiated with a Neutral at UBS | $52.00 |
| Aug 6, 2026 | Goldman Sachs | Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs | $55.00 |
| Jul 8, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP) | $80.00 |
| Jun 12, 2026 | UBS | CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens | $80.00 |
| Jun 11, 2026 | Morgan Stanley | Morgan Stanley Assumes CRISPR Therapeutics (CRSP) at Equalweight | $60.00 |
| May 13, 2026 | Bernstein | Crispr Therapeutics price target raised to $56 from $50 at Bernstein | $56.00 |
| May 11, 2026 | Evercore ISI | Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI | $76.00 |
| Feb 17, 2026 | Morgan Stanley | Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley | $33.00 |
| Feb 14, 2026 | Chardan Capital | Crispr Therapeutics price target raised to $76 from $74 at Chardan | $76.00 |
| Feb 13, 2026 | Evercore ISI | Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI | $74.00 |
| Feb 13, 2026 | Needham | Crispr Therapeutics price target raised to $82 from $80 at Needham | $82.00 |
| Nov 26, 2025 | Chardan Capital | Crispr Therapeutics price target lowered to $74 from $82 at Chardan | $74.00 |
| Nov 11, 2025 | RBC Capital | CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital | $50.00 |
| Oct 13, 2025 | Wells Fargo | Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo | $75.00 |
| Feb 3, 2025 | H.C. Wainwright | Crispr Therapeutics initiated with a Buy at H.C. Wainwright | $65.00 |
- 12 firms rate CRSP: 7 buy, 5 hold, 0 sell.
- The average price target is $63.17 from 6 analysts, from $52.00 to $80.00.
Updated 2026-11-02 23:11 UTC